WA-VIRTUOZZO
15.3.2022 12:02:04 CET | Business Wire | Press release
Virtuozzo , the alternative cloud platform leader, announced today that it will preview at CloudFest 2022 two never-before-seen solutions designed to help service providers bring to market modern cloud-based solutions that answer long-ignored market needs. The products are the PaaS-focused Virtuozzo Application Platform for WordPress and Virtuozzo Hybrid Server Lite. Framing their value proposition, Virtuozzo executives will deliver two keynote presentations outlining the current industry trends and landscape shaping the need for those services. The sessions will also introduce practical strategies for service providers to integrate and deploy the new solutions in ways that help them increase competitive positioning while growing their business.
Attendees can visit Virtuozzo, a platinum event sponsor, at Stand C01 throughout the show (March 22 – 24) in Europa-Park, Germany. Additionally, a special on-site promotion will give service providers six months free licensing for key solutions showcased during the conference.
Virtuozzo: Bringing Cloud to All
As a company, Virtuozzo has strategically evolved over the last several years to fill a polarizing void in the cloud enablement market. The most common paths to the cloud leverage hyperscaler or enterprise-centric platforms that are generally inflexible, cost-prohibitive, and too complex for non-specialized end users to manage. This puts many businesses, particularly small- to medium-sized ones, at a disadvantage. Which is where Virtuozzo comes in.
“There was an inherent promise in the beginning that cloud would be easy. Accessible to all. In reality, that is not how things panned out,” said Alex Fine, CEO, Virtuozzo. “Virtuozzo is solving that problem through collaborative partnerships with service providers that empower them to become full-service, alternative cloud providers.”
Virtuozzo develops and delivers the most comprehensive cloud platform stack purpose built for service providers. That infrastructure allows services providers to quickly carve out a wide portfolio of cloud services that are easy to use, easy to manage, and easy to scale. This frees them to then focus on areas where they can strongly differentiate, from the delivery of unique products and skills to high-touch customer support.
Virtuozzo Keynote Presentations
The Service Provider Landscape in 2022: Where is the Low-Hanging Fruit?
March 22 at 3:45 PM CET
Carlos Rego, Virtuozzo’s VP of Strategic Development, addresses the roller coaster ride that has been the experience of hosters, MSPs and cloud providers over the past decade. He provides expert perspective on the complex landscape they currently operate in, how the industry is evolving, and how these service providers can strategically grow their businesses without overly taxing their operations.
WordPress Hosting? It’s Time to Grow Up.
March 23 at 4:40 PM CET
In his second presentation, Carlos Rego will introduce viable revenue-generating opportunities surrounding the booming $500B+ WordPress economy. With new PaaS capabilities via Virtuozzo Application Platform for WordPress targeting business-critical WordPress sites, service providers can strengthen their businesses while helping modernize an enormous ecosystem that can be argued is antiquated today.
Schedule a Meeting
To meet with a Virtuozzo team member on site, contact info@Virtuozzo.com .
About Virtuozzo
Virtuozzo (www.virtuozzo.com ) provides the leading alternative cloud platform for service providers, enabling them to sell cloud services that are more accessible, more affordable and easier to use than hyperscaler solutions. The company’s legacy includes developing the first commercially available container technology and being a major contributor to numerous virtualization and open-source projects for more than 20 years. Today, Virtuozzo cloud solutions are used by more than 700 Cloud Service Providers, Managed Service Providers and Hosting Providers in 80 countries. Virtuozzo is based in Schaffhausen, Switzerland, and has more than 320 employees across the U.S., UK, Europe, and Asia-Pacific.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220315005472/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom